Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.76
+0.06500.39%
Post-market: 16.820.0611+0.36%19:59 EDT
Volume:5.20M
Turnover:87.53M
Market Cap:13.37B
PE:-14.99
High:17.32
Open:16.96
Low:16.66
Close:16.69
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.45
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.22
PE(LYR):-11.60

Loading ...

Summit Therapeutics shareholders approve 8 million-share increase to 2020 stock incentive plan

Reuters
·
Jun 13

Summit Therapeutics Co-CEO Mahkam Zanganeh reports purchase of 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics co-CEO Robert W. Duggan acquires 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics Withdraws Public Offering Due to Market Conditions

MT Newswires Live
·
Jun 11

Summit Therapeutics withdraws proposed underwritten public offering

TIPRANKS
·
Jun 11

BUZZ-Summit Therapeutics rebounds after pulling stock offering

Reuters
·
Jun 11

BRIEF-Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing

Reuters
·
Jun 11

Summit Therapeutics - No Securities to Be Sold in Proposed Underwritten Public Offering - SEC Filing

THOMSON REUTERS
·
Jun 11

Summit Therapeutics Stock Slides to 52-Week Low on Plans for Secondary Offering

Dow Jones
·
Jun 11

Summit Therapeutics falls -10.2%

TIPRANKS
·
Jun 11

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jun 10

BRIEF-Summit Therapeutics Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 10

Summit Therapeutics launches USD 500 million common stock offering

Reuters
·
Jun 10

Summit Therapeutics - Commences $500 Mln Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Jun 10

Summit Therapeutics - Proceeds to Fund Ivonescimab R&D, Working Capital, and General Corporate Purposes

THOMSON REUTERS
·
Jun 10

Summit Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 10

Summit Therapeutics: Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Jun 10

Summit Therapeutics (SMMT) Is Down 6.0% After New Ivonescimab ASCO Data - Has The Bull Case Changed?

Simply Wall St.
·
Jun 08

The Era of the One-Size-Fits-All Cancer Drug Is Ending -- Heard on the Street -- WSJ

Dow Jones
·
Jun 06

Summit Therapeutics Co-CEO Robert W. Duggan reports purchase of 100,000 common shares for $1.46 million

Reuters
·
Jun 05